4F-EPH
4-fluoroethylphenidate
Viewing r1 — May 11, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
4F-EPH (4-fluoroethylphenidate) is a synthetic stimulant of the phenidate class. It is the fluorinated structural analog of ethylphenidate, with greater potency at the transporters that recycle dopamine and norepinephrine.[1] It blocks those transporters, raising levels of both neurotransmitters and producing stimulation and euphoria.[2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
amphetamine, cocaine, methylphenidate +2 moreamphetamine, cocaine, methylphenidate, ethylphenidate, 4F-MPH show less
4F-EPH appeared on research chemical markets in mid-2015, most likely developed as a structural workaround after Ethylphenidate was temporarily banned in the United Kingdom.[3] It spread through European markets through 2016, drawing detections in France, the UK, and over a dozen other countries.[4] It remains available through some research chemical channels but is now controlled in the United Kingdom, Germany, Canada, and several other nations.[3]
Subjective effects include stimulation, euphoria, focus, and sociability enhancement. More euphoric and less purely stimulating than the closely related 4F-MPH, the experience tilts toward recreation rather than function.[5] Compulsive redosing urges, comedown depression, and nasal tissue damage from insufflation are characteristic unwanted effects.[6]
4F-EPH carries high addiction liability confirmed by rodent studies,[7] and no controlled toxicity data or lethal dose have been established.[5] Cardiovascular stress is the primary acute risk[8]: tolerance to euphoria builds faster than tolerance to that strain, so redosing escalates physical danger while the reward fades.[9] The evidence base is extremely thin — one case report, one rodent study, and European surveillance records.
History[edit]
Discovery
4F-EPH first appeared on research chemical markets in mid-to-late 2015, with the earliest user discussions on the Bluelight forum in October of that year.[6] No academic synthesis or patent has been identified as its origin. Adding a fluorine atom to the ethylphenidate scaffold created a structurally novel compound that bypassed the UK's April 2015 ban while retaining stimulant effects.[3]
Detection and surveillance
The first official detections in Europe occurred in France and the United Kingdom in March 2016, documented through the EMCDDA's European Database on New Drugs.[4] Detections followed across Denmark, Slovenia, Spain, Estonia, Sweden, and Latvia. By November 2022, the UNODC Early Warning Advisory had recorded 32 reports of 4F-EPH, primarily from Europe and Japan.[5]
Academic investigation
The compound received no substance-specific academic study for seven years after its market appearance. The first published paper — a forensic case report of a 2016 death in Scotland — appeared in 2022.[5] The first laboratory study followed in 2026, confirming that animals reliably self-administered 4F-EPH and treated it as equivalent to methamphetamine and cocaine.[7]
The name follows standard novel psychoactive substance convention: "4F" denotes the fluorine at the 4-position of the phenyl ring, and "EPH" abbreviates ethylphenidate. Among phenidate users, 4F-EPH occupies a niche as the "recreational" fluorinated phenidate — contrasted with 4F-MPH, which is considered more functional and less euphoric.[6]
Chemistry[edit]
Structural class
4F-EPH belongs to the phenidate class — a family of synthetic stimulants built from the methylphenidate scaffold. It is the fluorinated structural analog of ethylphenidate, with a fluorine atom at the para position of the phenyl ring, and the ethyl ester counterpart of 4-fluoromethylphenidate. These structural relationships place it at the intersection of two modification axes explored in phenidate research.[10]
Molecular properties
Its molecular formula is C₁₅H₂₀FNO₂ (265.32 g/mol).[11] The fluorine at the para position increases lipophilicity and binding potency relative to the unfluorinated parent.[1] No published data describe its physical properties — melting point, solubility, and stability have not been characterized.[10]
Pharmacology[edit]
Mechanism of action
4F-EPH blocks the DAT (DAT) and NET (NET), preventing dopamine and norepinephrine from being recycled back into nerve cells. These neurotransmitters accumulate in the synapse, amplifying their signals. Unlike amphetamine-type stimulants, which force neurotransmitter release, 4F-EPH only blocks reuptake — confirmed for the phenidate class by Luethi and colleagues.[2]
No binding data have been published for 4F-EPH specifically. Based on its two structural modifications — the ethyl ester increases dopamine selectivity[12][13] and the 4-fluorine roughly doubles transporter potency[1] — 4F-EPH is inferred to be a potent, dopamine-selective reuptake inhibitor. inferred
Pharmacokinetics
No human pharmacokinetic data exist for 4F-EPH.[5] The liver breaks down phenidate compounds by cleaving the ester bond, producing an inactive metabolite; this extensive first-pass metabolism limits how much reaches the bloodstream intact.[14] Community-sourced data report oral onset at 10–25 minutes, total duration of 5–6 hours, and aftereffects lasting 4–12 hours.[15]
Neuroscience[edit]
Where it acts
4F-EPH's primary action is in the brain's mesolimbic pathway — the circuit running from the ventral tegmental area to the nucleus accumbens. Blocking the DAT here raises dopamine in ways that powerfully reinforce behavior; animals reliably self-administered the compound.[7] The compound also elevates dopamine and norepinephrine in the prefrontal cortex, where they support focused attention and working memory.[16]
Why it matters
The compulsive compulsive redosing urge is explained by a distinction between wanting and liking. Dopamine in the reward pathway drives wanting — the motivation to seek more — rather than liking, the actual pleasure. This is why the urge to redose persists even after the euphoric rush has faded.[5]
Repeated use strengthens the wanting signal through behavioral sensitization, while tolerance within a single session diminishes the rush.[9][17] The result is escalating compulsion alongside diminishing reward.
Key unknowns include 4F-EPH's actual dopamine-to-norepinephrine selectivity ratio, which remains a structural inference rather than a measured value. The reported 4–12 hour aftereffect period exceeds what is typical for methylphenidate, and whether this reflects an active metabolite, prolonged receptor occupancy, or neurotransmitter depletion is undetermined.
Subjective Effects[edit]
4F-EPH produces a warm, energized stimulant high with a clear euphoric quality. Thoughts sharpen, sociability comes easily, and surroundings feel more engaging. A mild empathogenic dimension sometimes surfaces in social contexts, though it is not a defining feature of the compound.
Among the fluorinated phenidates, 4F-EPH sits on the recreational end — more euphoric than 4F-MPH and better suited to recreation than sustained work.[6] Users familiar with ethylphenidate describe a comparably euphoric character, with reportedly less compulsive redosing pressure than the parent compound.
Effect Grid
Clear stimulation, euphoria, and focus enhancement define this range. Thought acceleration and analysis enhancement are noticeable. Motivation enhancement and a drive to engage in tasks or conversation become prominent. Sociability enhancement and mild empathogenic qualities — described as gentle affectionate warmth — may emerge in social settings.
Appetite suppression is reliable. Pupil dilation becomes noticeable. Vasoconstriction may produce cool extremities. Heart rate elevation is present but typically not distressing. Spontaneous body sensations and tactile euphoria may be felt during the onset phase, fading into sustained stimulation.
Compulsive redosing urge may appear at this range. Total duration is approximately 5–6 hours, with aftereffects (cognitive fatigue, residual wakefulness) persisting 4–12 hours.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual processing acceleration
Insomnia · Pupil dilation · Dry mouth · Heart rate perception changes · Restlessness · Dehydration sensation · Muscle tension · Physical fatigue · Body high · Bruxism · Excessive sweating · Headache · Sexual arousal enhancement · Motor control enhancement · Nausea · Trembling
Restlessness · Dehydration sensation · Muscle tension · Physical fatigue · Body high · Bruxism · Excessive sweating · Headache · Sexual arousal enhancement · Motor control enhancement · Nausea · Trembling
Cognitive fatigue · Analysis enhancement · Information processing enhancement · Cognitive dysphoria · Thought organization · Memory enhancement
Thought organization · Memory enhancement
Dysphoria · Irritability
Sociability enhancement · Flow state
Timeline
Initial absorption; subtle increase in alertness and mental clarity. Effects may be barely distinguishable from baseline.
Building stimulation and mood elevation. Focus sharpens, appetite suppression begins, and mild body lightness may emerge.
Full stimulation, euphoria, focus enhancement, and sociability. Appetite suppression, pupil dilation, and cardiovascular effects are most prominent. Compulsive redosing urge may appear.
Gradual decline in stimulation and euphoria. Residual wakefulness and appetite suppression persist. Irritability and cognitive fatigue may begin to emerge.
Extended aftereffects including cognitive fatigue, residual wakefulness or insomnia, potential irritability, and mild depression. Not a positive afterglow for most users.
⚠ Do not drive or operate heavy machinery for at least 12 hours after effects subside, as residual stimulation and cognitive fatigue may impair reaction time and judgment.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Mild
- Tolerance buildup
- moderate
- Tolerance reset
- 10 days
- Physical
- Moderate
- Psychological
- Moderate
- Compulsive redosing
- Moderate
- Dose escalation
- Moderate
- Cross-tol.
- amphetamine · cocaine · methylphenidate
Toxicity
No controlled toxicity studies, lethal dose determinations, or established lethal concentrations exist for 4F-EPH.[5] All toxicity assessments are inferred from class data for dopamine/norepinephrine reuptake inhibitors. inferred
- Cardiovascular: Rapid heart rate and high blood pressure, driven by elevated norepinephrine. At high doses: heart attack risk, irregular heartbeat, and dangerously high blood pressure.
- Neurological: Dilated pupils, tremor, agitation. At high doses: hallucinations, delirium, seizures.
- Temperature: Overheating at high doses, with risk of muscle breakdown and kidney failure.
Fatalities from phenidate overdose alone are rare when medical care is available.[8] Combining substances substantially increases risk.
Documented cases
One death involving 4F-EPH has been published — a 2016 case in Scotland where a causal connection could not be established from a single blood sample, and no lethal concentration has been determined.[5] Cases from the closely related 4F-MPH provide context: one user required hospitalization with sedation and antipsychotic treatment after a week of intranasal use,[18] and the first US fatality involved multiple other substances.[19]
Nasal toxicity
4F-EPH is corrosive to nasal tissue when insufflated, though reportedly less so than ethylphenidate.[6] Repeated intranasal use carries risk of tissue erosion and chronic inflammation.
Overdose management
No 4F-EPH-specific overdose protocols exist. Standard stimulant management applies[8]:
- Benzodiazepines are first-line treatment for agitation, seizures, and stimulant toxicity.
- Antipsychotics may be used for uncontrolled agitation or psychosis.
- Supportive care: IV fluids, cooling measures for overheating, heart monitoring.
- Avoid physostigmine.
Psychological risks
High doses or extended use can produce paranoia, auditory hallucinations, and delusional thinking — a risk that grows with sleep deprivation.[17][9] Noradrenergic activation drives anxiety during the comedown. After sustained stimulation, neurotransmitter depletion produces depressive symptoms, anhedonia, and fatigue.[5]
Compulsive redosing urges are present, though reportedly less severe than with Ethylphenidate.[6]
Tolerance and dependence
Tolerance
Acute tolerance to euphoria develops within a single session — the initial rush fades with each dose.[5] Longer-term tolerance builds with sustained use,[9] and cross-tolerance exists with other stimulants including amphetamine, cocaine, and methylphenidate.[9]
Community estimates suggest a tolerance half-life of approximately 5 days and full reset at 1.5 weeks. These values have no published pharmacological basis. safety citation needed
Dependence
Dopaminergic reuptake inhibitors carry high addiction liability.[9][17] Rodent data confirm this: animals reliably self-administered 4F-EPH and treated it as equivalent to methamphetamine and cocaine.[7]
Physical dependence is moderate by class inference. Withdrawal typically brings fatigue, excessive sleep, appetite enhancement, low mood, and slowed movement — uncomfortable but not physiologically dangerous. Psychological dependence driven by the reinforcing dopaminergic effects is the primary concern. inferred
Drug interactions
Tramadol
Classified as lethal. Tramadol inhibits both serotonin and norepinephrine reuptake alongside its opioid action.[20] Combining it with 4F-EPH creates dangerous noradrenergic overload and serotonin syndrome risk — a life-threatening overheating and seizure response with a mortality rate up to 12% in severe cases.[20] safety citation needed
MDMA
Classified as dangerous. MDMA releases serotonin, dopamine, and norepinephrine simultaneously. Combining it with a reuptake inhibitor multiplies cardiovascular strain; a controlled study found the combination produced significantly greater cardiovascular effects and more adverse events than either drug alone.[21]
Alcohol
Classified as unknown. A specific metabolic interaction known for methylphenidate and alcohol does not apply to 4F-EPH, which already carries an ethyl ester.[14][12] Standard risks of impaired judgment and dehydration apply to any stimulant-alcohol combination.
General interaction principles
As a dopamine/norepinephrine reuptake inhibitor, 4F-EPH poses specific risks in combination:
- MAOIs: Dangerous blood pressure spike from impaired neurotransmitter breakdown combined with elevated synaptic levels.
- Other stimulants: Additive cardiovascular toxicity.
- Serotonergic agents (SNRIs, SSRIs, serotonergic psychedelics): Potential serotonin syndrome.[20]
Contraindications
No substance-specific contraindication data exist. The following are inferred from the reuptake inhibitor class and methylphenidate prescribing precedent[8]: inferred
- Heart disease, high blood pressure, irregular heartbeat (absolute): Stimulant cardiovascular effects worsen pre-existing heart conditions.
- History of psychosis or bipolar disorder (absolute): Dopaminergic stimulation can trigger or worsen psychotic episodes and manic states.
- Concurrent MAOI use (absolute): Risk of dangerously high blood pressure.
- Concurrent tramadol or serotonergic agent use (absolute): Serotonin syndrome risk.
- Seizure disorder (relative): Stimulants may lower seizure threshold at high doses.
- Pregnancy and lactation (absolute): No reproductive safety data exist.
- Liver impairment (relative): The liver enzyme responsible for metabolizing this compound may function poorly, increasing drug exposure.
Harm Reduction[edit]
Forms & Identification
4F-EPH circulates through research chemical vendors with no pharmaceutical reference form. Reagent testing and analytical services (GC-MS, LC-MS/MS) are the most reliable tools for confirming identity.[10] Phenidate analogs can degrade during analysis, complicating identification even in laboratory settings.
Precise weighing is essential: no established dose-response relationship exists, and the margin between a functional dose and one producing cardiovascular strain is undefined.
Guidelines
- Test every batch with reagent kits and, where possible, analytical services before use.
- Weigh doses with a milligram-precision scale — never eyeball powder doses.
- Choose oral administration over insufflation or vaporization to reduce cardiovascular spike intensity and nasal tissue damage.
- Set a firm dose limit before the session begins; the urge to redose will feel more compelling than the situation warrants.
- Do not redose once euphoric effects have faded — cardiovascular load persists after the subjective high diminishes.
- Eat a meal beforehand; stimulants suppress appetite and can lead to prolonged fasting.
- Keep water accessible throughout and maintain hydration.
- Avoid use on consecutive days; allow full tolerance reset periods between sessions.
- Have a trusted person aware of what was taken and when.
Set & Setting
The wakefulness-promoting effects and compulsive redosing urge make unsupervised extended sessions the highest-risk scenario — sleep deprivation compounds stimulant psychosis risk with each additional hour. A calm, familiar environment with access to water, food, and a trusted companion is preferable. Social settings may enhance prosocial effects but also reduce awareness of escalating cardiovascular symptoms.
Aftercare & integration. The comedown involves neurotransmitter depletion — expect fatigue, low mood, difficulty concentrating, and appetite enhancement for 24–48 hours after use. Sleep recovery is the priority: use the first available window to sleep, even if residual stimulation makes this difficult.
Eat nutrient-dense meals during and after the comedown. Avoid caffeine and other stimulants for at least 24 hours, as they extend the depletion cycle. If depressive symptoms persist beyond 72 hours or become severe, seek professional support.
Recovery & Support
Compulsive use patterns with 4F-EPH typically involve escalating frequency and dose as tolerance develops. Recognizing this pattern early — particularly redosing despite diminishing returns — is the clearest signal that use has moved beyond occasional.
SMART Recovery and similar programs offer structured approaches to stimulant use disorders. Professional support from an addiction specialist is recommended for anyone who has difficulty maintaining intended limits. Crisis resources: SAMHSA National Helpline (US): 1-800-662-4357; Talk to Frank (UK): 0300 123 6600.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: chest pain, severe headache, seizure, loss of consciousness, or body temperature hot enough to feel through clothing are emergencies, not discomfort. Paranoid ideation with loss of contact with reality is a psychiatric emergency.
Immediate steps:
- 1. Call emergency services if any of the above symptoms are present.
- 2. Keep the person still and in a cool area; remove excess clothing.
- 3. Do not restrain unless there is immediate danger of self-harm.
- 4. Do not induce vomiting.
- 5. If conscious, offer small sips of water.
What to tell the dispatcher: Name the substance (4F-EPH, a stimulant similar to methylphenidate), the amount taken if known, the time of the last dose, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Legal Status[edit]
4F-EPH is not scheduled under any international convention.[5] National controls exist in over a dozen jurisdictions, primarily in Europe.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not specifically scheduled | Not listed under the Controlled Substances Act. May fall under the Federal Analogue Act (21 U.S.C. § 813) as a structural analog of Schedule II methylphenidate if intended for human consumption. No prosecution under the Analogue Act for 4F-EPH has been identified. citation needed |
| United Kingdom | Class B (Misuse of Drugs Act 1971) | Scheduled under the Misuse of Drugs Act 1971 (Amendment) Order 2017, effective May 31, 2017. Also covered by the Psychoactive Substances Act 2016.[3] |
| Germany | Controlled (NpSG) | Covered under the Neue-psychoaktive-Stoffe-Gesetz (NpSG), effective November 26, 2016. Production and supply prohibited; simple possession not penalized under NpSG.[22] |
| Canada | Controlled | Nationally scheduled.[22] |
| Sweden | Controlled | Nationally scheduled since 2018.[22] |
| Hungary | Controlled | Nationally scheduled since April 2021.[22] |
| Finland | Controlled | Nationally scheduled.[22] |
| Estonia | Controlled | Nationally scheduled.[22] |
| Norway | Controlled | Nationally scheduled.[22] |
| Lithuania | Controlled | Nationally scheduled.[22] |
| Switzerland | Controlled | Nationally scheduled.[22] |
| Turkey | Controlled | Nationally scheduled.[22] |
| Australia | Not specifically scheduled | No evidence of specific scheduling identified. Likely subject to import restrictions under the Therapeutic Goods Administration (TGA) framework. citation needed |
Analog act considerations
In the United States, the Federal Analogue Act may extend controls to 4F-EPH as a structural analog of methylphenidate (Schedule II), but only if intended for human consumption. Whether a court would find it "substantially similar" has not been tested — two structural modifications separate it from the scheduled parent, and the legal significance of that degree of divergence is uncertain. citation needed
Legal status changes frequently and varies by jurisdiction. This information reflects published records as of the article's last update and is not legal advice.
references
- [1] ^abcMcLaughlin G, Morris N, Kavanagh PV, Power JD, Dowling G, Twamley B, O'Brien J, Hessman G, Murphy B, Walther D, Partilla JS, Baumann MH, Brandt SD (2017) Analytical characterization and pharmacological evaluation of the new psychoactive substance 4-fluoromethylphenidate (4F-MPH) and differentiation between the (±)-threo and (±)-erythro diastereomers — Drug Testing and Analysis doi:10.1002/dta.2167
- [2] ^abLuethi D, Kaeser PJ, Brandt SD, Krähenbuhl S, Hoener MC, Liechti ME (2018) Pharmacological profile of methylphenidate-based designer drugs — Neuropharmacology doi:10.1016/j.neuropharm.2017.08.020
- [3]
- [4]
- [5]
- [6]